PSPC1 C-terminal containing an extension of more than 10 but no greater than 131 amino acid residues exhibits anticancer activity. The anti-tumor activity of PSPC1-CT131 suppresses tumor cell growth progression metastasis via decreasing oncogenic PSPC1PTK6. Also disclosed a reagent kitmethod for predicting tumor progression, metastasis,prognosis in a cancer patient.

PSPC1 is the contextual determinant of oncogenic PSPC1/PTK6/β-catenin axis highlight a subcellular translocation switch. PSPC1-CT131 is a dual inhibitor of PSPC1tyrosine kinase PTK6 for potential improvement of cancer therapy.

PSPC1 C-terminal containing an anti-tumor activity of PSPC1-CT131 suppresses tumor cell growth, progression, metastasis via decreasing oncogenic PSPC1PTK6. An absencea decrease in the expression level of PSPC1 pY523 in nucleus via antibody against PSPC1 Tyr 523 phosphorylation (pY523) compared to a control tissue sample indicates tumor progression, metastasispoor tumor prognosis.